322 related articles for article (PubMed ID: 35807171)
1. Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias.
Gareri C; Polimeni A; Giordano S; Tammè L; Curcio A; Indolfi C
J Clin Med; 2022 Jul; 11(13):. PubMed ID: 35807171
[TBL] [Abstract][Full Text] [Related]
2. The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname MH; Rocha VZ; Santos RD
Curr Atheroscler Rep; 2021 Jun; 23(8):40. PubMed ID: 34146170
[TBL] [Abstract][Full Text] [Related]
3. A new dawn for managing dyslipidemias: The era of rna-based therapies.
Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotides for the treatment of dyslipidaemia.
Visser ME; Witztum JL; Stroes ES; Kastelein JJ
Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
[TBL] [Abstract][Full Text] [Related]
5. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
Warden BA; Duell PB
J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
[TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
7. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
8. Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects.
Filippatos TD; Liontos A; Christopoulou EC; Elisaf MS
Curr Vasc Pharmacol; 2019; 17(4):332-340. PubMed ID: 29424317
[TBL] [Abstract][Full Text] [Related]
9. Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia.
Kosmas CE; Bousvarou MD; Sourlas A; Papakonstantinou EJ; Peña Genao E; Echavarria Uceta R; Guzman E
Clin Pharmacol; 2022; 14():49-59. PubMed ID: 35873366
[TBL] [Abstract][Full Text] [Related]
10. Inclisiran for the treatment of dyslipidemia.
Nishikido T; Ray KK
Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410
[TBL] [Abstract][Full Text] [Related]
11. Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia.
Kosmas CE; Muñoz Estrella A; Sourlas A; Silverio D; Hilario E; Montan PD; Guzman E
Diseases; 2018 Jul; 6(3):. PubMed ID: 30011788
[TBL] [Abstract][Full Text] [Related]
12. Inclisiran in dyslipidemia.
Kosmas CE; Muñoz Estrella A; Sourlas A; Pantou D
Drugs Today (Barc); 2021 May; 57(5):311-319. PubMed ID: 34061126
[TBL] [Abstract][Full Text] [Related]
13. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
[TBL] [Abstract][Full Text] [Related]
14. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
Athyros VG; Katsiki N; Dimakopoulou A; Patoulias D; Alataki S; Doumas M
Curr Pharm Des; 2018; 24(31):3638-3646. PubMed ID: 30306859
[TBL] [Abstract][Full Text] [Related]
15. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
Dragan S; Serban MC; Banach M
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
[TBL] [Abstract][Full Text] [Related]
16. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases.
Landmesser U; Poller W; Tsimikas S; Most P; Paneni F; Lüscher TF
Eur Heart J; 2020 Oct; 41(40):3884-3899. PubMed ID: 32350510
[TBL] [Abstract][Full Text] [Related]
17. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
18. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
Landmesser U; Haghikia A; Leiter LA; Wright RS; Kallend D; Wijngaard P; Stoekenbroek R; Kastelein JJ; Ray KK
Cardiovasc Res; 2021 Jan; 117(1):284-291. PubMed ID: 32243492
[TBL] [Abstract][Full Text] [Related]
19. RNA-targeted therapeutics for lipid disorders.
Tsimikas S
Curr Opin Lipidol; 2018 Dec; 29(6):459-466. PubMed ID: 30234555
[TBL] [Abstract][Full Text] [Related]
20. New Trends in Dyslipidemia Treatment.
Jang AY; Lim S; Jo SH; Han SH; Koh KK
Circ J; 2021 May; 85(6):759-768. PubMed ID: 33177309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]